Basic characteristic of 776 patients with relapsed AML after RIC HSCT in CR
| . | Total n = 776 . | Patients with basic data n = 513 . | Patients with detailed report n = 263 . | P . |
|---|---|---|---|---|
| Patient sex, n (%) | ||||
| Male | 422 (54) | 291 (57) | 131 (50) | .07 |
| Female | 354 (46) | 222 (43) | 132 (50) | |
| Median age, y (range) | 55.7 (18-76) | 55.7 (18-76) | 55.7 (18-71) | .83 |
| Cytogenetics according to SWOG criteria26 , n (%) | ||||
| Good | 22 (3) | 9 (4) | 13 (6) | .07 |
| Intermediate | 326 (42) | 173 (77) | 153 (67) | |
| Poor | 103 (17) | 42 (19) | 61 (27) | |
| Missing | 325 | 289 | 36 | |
| Median date of transplantation | September 2005 | November 2005 | March 2005 | < .0001 |
| Stage at transplant, n (%) | ||||
| CR1 | 568 (73) | 370 (72) | 198 (75) | .6 |
| CR2 | 193 (25) | 132 (26) | 61 (23) | |
| CR3 | 15 (2) | 11 (2) | 4 (2) | |
| Donor relation, n (%) | ||||
| HLA ID | 476 (61) | 304 (59) | 172 (65) | .10 |
| Other | 300 (39) | 209 (41) | 913 (5) | |
| Sources of stem cells, n (%) | ||||
| BM | 89 (11) | 66 (13) | 23 (9) | .02 |
| PB | 665 (86) | 428 (83) | 237 (90) | |
| CB | 22 (3) | 19 (4) | 3 (1) | |
| ATG as part of GVHD prevention, n (%) | ||||
| No | 412 | 260 (70) | 152 (58) | .002 |
| Yes | 224 | 113 (30) | 111 (42) | |
| TBI as part of the conditioning, n (%) | ||||
| No | 541 | 363 (71) | 178 (68) | .3 |
| Yes | 232 | 147 (29) | 85 (32) | |
| Acute GVHD after first HSCT, n (%) | ||||
| Grade 0/I | 621 | 399 | 222 (85) | .62 |
| ≥ grade II | 115 | 78 (16) | 39 (15) | |
| Chronic GVHD after first HSCT, n (%) | ||||
| No | 429 (55) | 257 (50) | 172 (65) | .82 |
| Limited | 118 (15) | 68 (13) | 50 (19) | |
| Extensive | 97 (13) | 60 (12) | 37 (14) | |
| Missing | 132 (17) | 128 (25) | 4 (2) | |
| Median interval from first HSCT to relapse (mo, range) | 5.54 (1-83) | 5.7 (1-83) | 5.02 (1-60) | .42 |
| . | Total n = 776 . | Patients with basic data n = 513 . | Patients with detailed report n = 263 . | P . |
|---|---|---|---|---|
| Patient sex, n (%) | ||||
| Male | 422 (54) | 291 (57) | 131 (50) | .07 |
| Female | 354 (46) | 222 (43) | 132 (50) | |
| Median age, y (range) | 55.7 (18-76) | 55.7 (18-76) | 55.7 (18-71) | .83 |
| Cytogenetics according to SWOG criteria26 , n (%) | ||||
| Good | 22 (3) | 9 (4) | 13 (6) | .07 |
| Intermediate | 326 (42) | 173 (77) | 153 (67) | |
| Poor | 103 (17) | 42 (19) | 61 (27) | |
| Missing | 325 | 289 | 36 | |
| Median date of transplantation | September 2005 | November 2005 | March 2005 | < .0001 |
| Stage at transplant, n (%) | ||||
| CR1 | 568 (73) | 370 (72) | 198 (75) | .6 |
| CR2 | 193 (25) | 132 (26) | 61 (23) | |
| CR3 | 15 (2) | 11 (2) | 4 (2) | |
| Donor relation, n (%) | ||||
| HLA ID | 476 (61) | 304 (59) | 172 (65) | .10 |
| Other | 300 (39) | 209 (41) | 913 (5) | |
| Sources of stem cells, n (%) | ||||
| BM | 89 (11) | 66 (13) | 23 (9) | .02 |
| PB | 665 (86) | 428 (83) | 237 (90) | |
| CB | 22 (3) | 19 (4) | 3 (1) | |
| ATG as part of GVHD prevention, n (%) | ||||
| No | 412 | 260 (70) | 152 (58) | .002 |
| Yes | 224 | 113 (30) | 111 (42) | |
| TBI as part of the conditioning, n (%) | ||||
| No | 541 | 363 (71) | 178 (68) | .3 |
| Yes | 232 | 147 (29) | 85 (32) | |
| Acute GVHD after first HSCT, n (%) | ||||
| Grade 0/I | 621 | 399 | 222 (85) | .62 |
| ≥ grade II | 115 | 78 (16) | 39 (15) | |
| Chronic GVHD after first HSCT, n (%) | ||||
| No | 429 (55) | 257 (50) | 172 (65) | .82 |
| Limited | 118 (15) | 68 (13) | 50 (19) | |
| Extensive | 97 (13) | 60 (12) | 37 (14) | |
| Missing | 132 (17) | 128 (25) | 4 (2) | |
| Median interval from first HSCT to relapse (mo, range) | 5.54 (1-83) | 5.7 (1-83) | 5.02 (1-60) | .42 |
RIC indicates reduced intensity conditioning; BM, bone marrow; PB, peripheral blood; CB, cord blood; HSCT, hematopoietic stem cell transplantation; CR, complete remission; ATG, anti thymocyte globulin; TBI, total body irradiation; and GVHD, graft-versus-host disease.